Home - Kumar Group

Welcome to Our Group

We are delighted to have you explore our research. Our group is dedicated to advancing the frontiers of organic chemistry, medicinal chemistry, and drug discovery.

Our research centres on the discovery and development of novel bioactive molecules for industrial and medical applications. Naturally produced chemicals play fundamental roles in biological systems, yet many are available only in trace amounts. Through innovative organic synthesis, we access these molecules and their analogues, enabling full assessment of biological activity, mode of action, and the development of new therapeutic leads. Our work is multi-disciplinary, combining synthetic organic chemistry, molecular modelling, and biological screening.

Our Research

Discover our research areas in Organic chemistry and drug discovery

Explore All Research

Organic/Medicinal Chemistry

Our group focuses on the design and synthesis of novel drug candidates for various therapeutic targets, with a particular emphasis on cancer and infectious diseases.

Drug Discovery

We employ state-of-the-art techniques in Organic/Medicinal Chemistry, including structure-based drug design, fragment-based drug discovery, and high-throughput screening.

Chemical Biology

Our research integrates chemical synthesis with biological studies to understand disease mechanisms and develop new therapeutic strategies.

Computational Drug Discovery

We use AI, machine learning, deep learning, molecular docking, and simulation to accelerate drug discovery and design.

Latest News

Congratulations to Dr. Valerio on a New ChemMedChem Publication

July 13, 2026

Congratulations to Dr. Valerio Falasca and co-authors on a new paper in ChemMedChem reporting novel isoflavene TBK1 inhibitors with anti-inflammatory activity, including lead compound 7a with an IC50 of 0.13...

Congratulations to Dr. Valerio on a New ChemMedChem Publication

July 13, 2026

Congratulations to Dr. Valerio Falasca and co-authors on a new paper in ChemMedChem reporting novel isoflavene TBK1 inhibitors with anti-inflammatory activity, including lead compound 7a with an IC50 of 0.13...

Happy Birthday, Vidia Nuraini!

July 05, 2026

The Kumar Research Group extends warm birthday wishes to Vidia Nuraini. We appreciate her dedication to antimicrobial resistance research and wish her continued success.

Kumar Group Celebrates Vidia Nuraini at the UNSW Science 2026 Postgraduate Research Showcase

June 30, 2026

Congratulations to Vidia Nuraini on representing the Kumar Group at the UNSW Science 2026 Postgraduate Research Showcase, participating in both the One Minute Thesis and Poster Competition under the theme...

Congratulations to Nathan Carey on ACS Infectious Diseases Publication

June 29, 2026

Congratulations to Nathan Carey and co-authors on a new review in ACS Infectious Diseases on contact lens-associated infections and biomaterial-based solutions—a timely contribution published in a leading high-impact journal.

Welcome Dr Md Musfizur Hassan to the Kumar Group

June 23, 2026

Delighted to welcome Dr Md Musfizur Hassan to the Kumar Research Group as a Postdoctoral Research Fellow. Dr Hassan brings extensive expertise in peptide chemistry, pharmaceutical formulation, and bioconjugation.